BibTex format
@article{Schmit:2024:10.1016/S1473-3099(23)00816-2,
author = {Schmit, N and Topazian, HM and Natama, HM and Bellamy, D and Traoré, O and Somé, MA and Rouamba, T and Tahita, MC and Bonko, MDA and Sourabié, A and Sorgho, H and Stockdale, L and Provstgaard-Morys, S and Aboagye, J and Woods, D and Rapi, K and Datoo, MS and Lopez, FR and Charles, GD and McCain, K and Ouedraogo, J-B and Hamaluba, M and Olotu, A and Dicko, A and Tinto, H and Hill, AVS and Ewer, KJ and Ghani, AC and Winskill, P},
doi = {10.1016/S1473-3099(23)00816-2},
journal = {Lancet Infectious Diseases},
pages = {465--475},
title = {The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study},
url = {http://dx.doi.org/10.1016/S1473-3099(23)00816-2},
volume = {24},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and cost-effectiveness of vaccine introduction across sub-Saharan Africa. METHODS: We fitted a semi-mechanistic model of the relationship between anti-circumsporozoite protein antibody titres and vaccine efficacy to data from 3 years of follow-up in the phase 2b trial of R21/Matrix-M in Nanoro, Burkina Faso. We validated the model by comparing predicted vaccine efficacy to that observed over 12-18 months in the phase 3 trial. Integrating this framework within a mathematical transmission model, we estimated the cases, malaria deaths, and disability-adjusted life-years (DALYs) averted and cost-effectiveness over a 15-year time horizon across a range of transmission settings in sub-Saharan Africa. Cost-effectiveness was estimated incorporating the cost of vaccine introduction (dose, consumables, and delivery) relative to existing interventions at baseline. We report estimates at a median of 20% parasite prevalence in children aged 2-10 years (PfPR2-10) and ranges from 3% to 65% PfPR2-10. FINDINGS: Anti-circumsporozoite protein antibody titres were found to satisfy the criteria for a surrogate of protection for vaccine efficacy against clinical malaria. Age-based implementation of a four-dose regimen of R21/Matrix-M vaccine was estimated to avert 181825 (range 38815-333491) clinical cases per 100000 fully vaccinated children in perennial settings and 202017 (29868-405702) clinical cases per 100000 fully vaccinated children in seasonal settings. Similar estimates were obtained for seasonal or hybrid implementation. Under an assumed vaccine dose price of US$3, the incremental cost per clinical case averted was $7 (range 4-48) in perennial settings and $6 (3-63) in seasonal settings and the incremental cost per DALY averted was $34 (29-139) in perennial s
AU - Schmit,N
AU - Topazian,HM
AU - Natama,HM
AU - Bellamy,D
AU - Traoré,O
AU - Somé,MA
AU - Rouamba,T
AU - Tahita,MC
AU - Bonko,MDA
AU - Sourabié,A
AU - Sorgho,H
AU - Stockdale,L
AU - Provstgaard-Morys,S
AU - Aboagye,J
AU - Woods,D
AU - Rapi,K
AU - Datoo,MS
AU - Lopez,FR
AU - Charles,GD
AU - McCain,K
AU - Ouedraogo,J-B
AU - Hamaluba,M
AU - Olotu,A
AU - Dicko,A
AU - Tinto,H
AU - Hill,AVS
AU - Ewer,KJ
AU - Ghani,AC
AU - Winskill,P
DO - 10.1016/S1473-3099(23)00816-2
EP - 475
PY - 2024///
SN - 1473-3099
SP - 465
TI - The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
T2 - Lancet Infectious Diseases
UR - http://dx.doi.org/10.1016/S1473-3099(23)00816-2
UR - https://www.ncbi.nlm.nih.gov/pubmed/38342107
UR - https://www.sciencedirect.com/science/article/pii/S1473309923008162
UR - http://hdl.handle.net/10044/1/109562
VL - 24
ER -